260 related articles for article (PubMed ID: 32064552)
1. Exploratory cost-effectiveness analysis of
Gordon LG; Elliott TM; Joshi A; Williams ED; Vela I
Clin Exp Metastasis; 2020 Apr; 37(2):305-312. PubMed ID: 32064552
[TBL] [Abstract][Full Text] [Related]
2. How does
Bianchi L; Schiavina R; Borghesi M; Ceci F; Angiolini A; Chessa F; Droghetti M; Bertaccini A; Manferrari F; Marcelli E; Cochetti G; Porreca A; Castellucci P; Fanti S; Brunocilla E
Int J Urol; 2019 Aug; 26(8):804-811. PubMed ID: 31083784
[TBL] [Abstract][Full Text] [Related]
3. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
7. Intention-to-Treat Analysis of
Schwenck J; Olthof SC; Pfannenberg C; Reischl G; Wegener D; Marzec J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
J Nucl Med; 2019 Oct; 60(10):1359-1365. PubMed ID: 30850491
[TBL] [Abstract][Full Text] [Related]
8.
Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
10. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
11. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
12. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
14. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in
Freitag MT; Radtke JP; Afshar-Oromieh A; Roethke MC; Hadaschik BA; Gleave M; Bonekamp D; Kopka K; Eder M; Heusser T; Kachelriess M; Wieczorek K; Sachpekidis C; Flechsig P; Giesel F; Hohenfellner M; Haberkorn U; Schlemmer HP; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):776-787. PubMed ID: 27988802
[TBL] [Abstract][Full Text] [Related]
15.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
16.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract][Full Text] [Related]
18.
Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
[TBL] [Abstract][Full Text] [Related]
19. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of a
Rousseau C; Le Thiec M; Ferrer L; Rusu D; Rauscher A; Maucherat B; Frindel M; Baumgartner P; Fleury V; Denis A; Morel A; Varmenot N; Debeaupuis E; Campion L; Kraeber-Bodéré F
Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]